My doctor understands Alpha-1

For Healthcare Professionals

Alpha-1 diagnosis, treatment, and support

While Alpha-1 affects many aspects of patients' lives, the disease also impacts physicians and staff who need to care for these patients. This section can help healthcare professionals (HCPs) get the information they need to screen for, diagnose, and treat Alpha-1. Topics covered here include:

  • The importance of prompt, thorough, and accurate testing and diagnosis for Alpha-1
  • The clinical benefits of using Zemaira for the treatment of Alpha-1 associated emphysema
  • The broad range of materials and resources CSL Behring provides for HCPs
Which Patients Should You Test for Alpha-1?

See How Alpha-1 Affects the Lungs

Watch a video animation that shows the critical role of alpha1 antitrypsin in the lungs

Watch Video

Order the Alpha LabZ eZ Kit for Your Office

CSL Behring's new test kit makes it easy to receive prompt, accurate, and thorough test results

Read More

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.